COMPANY PROFILE

Artidis

Explore full profile

Develops a nanomechanical platform for rapid cancer diagnosis and personalized treatment optimization

Basel, SwitzerlandFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2019

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Artidis

ARTIDIS operates in the healthcare sector, focusing on the rapid diagnosis and treatment optimization for cancer patients. The company leverages its proprietary nanomechanical biomarker technology to detect cancer, assess its aggressiveness, and predict the likelihood of metastasis. ARTIDIS primarily serves healthcare professionals and cancer treatment centers, providing them with the ARTIDISNET platform. This platform integrates nanomechanical biomarkers with clinical data to guide personalized therapy choices, aiming to improve patient outcomes and reduce the incidence of over or undertreatment. The company generates revenue through the sale of its diagnostic platform and associated services to medical institutions and healthcare providers. ARTIDIS operates in the global healthcare market, with a particular focus on regions with advanced cancer treatment facilities. The business model is centered around providing cutting-edge diagnostic tools that enhance the accuracy and efficiency of cancer treatment plans, thereby improving the quality of life for patients and reducing healthcare costs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Basel, Switzerland
Employees: 90
Open positions: 20
Dealroom signal: 79.4/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Nanomaterials, Woman Founder, DT and LS, science-based
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Dec 2019	$8.8M	$35M	SMD MedicalTrade	↗
SEED✓Equity / VC	May 2019	$2.5M	$9.9M	Hemex	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Artidis website traffic

Latest recorded traffic for Artidis is 1.5K monthly website visits, up 7.1% over the last three months. Artidis's team grew 12.5% over the past year.

Latest monthly visits1.5K 3-month web change+7.1% 1-year team growth+12.5%

Monthly website visitsNov 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Backend Software EngineerZagreb, Zagreb, Croatia · Backend Development · Sep 1, 2026 Field Service EngineerHouston, TX · Other · Aug 28, 2026 Finance ManagerBasel, Basel, Switzerland · Finance · Aug 18, 2026 Medical Affairs & Scientific Engagement ManagerHouston, TX · Other · Aug 17, 2026 Business Operations ManagerHouston, TX · Business Development · Aug 13, 2026 Clinical Scientist (Medical Focus)Basel, Basel, Switzerland · Other · Aug 12, 2026 Scientific Communications & Digital Engagement ManagerHouston, TX · Marketing & Communication · Aug 11, 2026 Tissue Biophysicist – Cellular and Tissue ArchitectureZagreb, Zagreb, Croatia · Other · Aug 5, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LTLunaphore TechnologiesBuilds tumor analysis platforms performing immunohistochemistry using microfluidic technology	Tolochenaz, Switzerland	Acquired	88	$90M	$133M
HEHealshapePersonalized, resorbable bioprosthesis for natural breast reconstruction	Nantes, France	Operational
MDMLA DiagnosticsDeveloped a revolutionary prognostic test for early stage melanoma	Maastricht, Netherlands	Operational
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
DMDamae MedicalMedical device capable of seeing biological tissues in depth, at a cellular level and in vivo	Paris, France	Operational
OMONWARD MedicalNeurotechnology enabling recovery after spinal cord injury	Eindhoven, Netherlands	Operational
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
MBMaxWell BiosystemsProvides next generation high-content electrophysiology platforms to facilitate detailed investigation of cells in vitro	Zurich, Switzerland	Operational